Expert Interview
Continuing the Conversation (Part 2): Diving into Travere Therapeutics' Sparsentan in patients with IgA nephropathy ahead of the PDUFA
Ticker(s): TVTXInstitution: Massachussets General Hospital
- Director of Dialysis Services and the Medical Director Emerita of the Renal and Pancreas Transplantation at Massachusetts General Hospital; Professor of Medicine at Harvard Medical School.
- Treats approximately 15 patients with IgA Nephropathy.
- Research focus is on defining effective antirejection therapy directed against the T cell in both the efficacy of antithymocyte globulin (ATG) as well as the first human trials of the monoclonal antibody OKT3; Clinical focus on acute and chronic renal failure, Kidney transplants, UTIs and dialysis.
Roughly how many patients do you manage with IgA nephropathy?
Added By: c_adminOn a scale on 1-10, (10 being extremely excited) where would you rate your level of excitement for sparsentan?
Added By: c_adminGiven that IgAN requires a biopsy - how frequently is IgAN not diagnosed? And do you believe this will change in the future with more targeted therapies available?
Added By: christopholdenburgAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
